Non-Dilutive Funding for Infectious Diseases Research

There are many funding opportunities available for infectious diseases R&D. Main sources include National Institute of Allergy and Infectious Diseases (NIAID) of the NIH, Department of Defense (DoD) via Defense Advance Research Projects Agency (DARPA), Defense Threat Reduction Agency (DTRA), and USAMRMC, and Biomedical Advanced Research and Development Authority (BARDA).

National Institutes of Health (NIH)

National Institute of Allergy and Infectious Diseases (NIAID)

Many funding opportunities for infectious diseases are available through NIAID, which awards ~$6B in grants annually to support R&D. NIAID has a list of priority pathogens that are of interest.

NIAID awards the majority of its grants via the investigator-initiated Parent Announcements (Pre-Clinical / Clinical). Additional specific funding opportunities include:

1. International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)

This funding opportunity supports high-priority, regionally relevant infectious disease research in resource-constrained countries. Applicant organizations must be headquartered in non-U.S. resource-constrained countries.

Award Budget and Period: Applications may request a budget of up to $125,000 per year in direct cost and a maximum of $625,000 in direct costs over a five-year project period.

Due date: July 15, 2020; July 15, 2021; July 15 2022

2. Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)

This funding opportunity supports research that contributes to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine.

Award Budget and Period: $500K per year in direct costs of a period of five years.

Application Due Dates: October 5th, February 5th, June 5th

3. Advancing Research Need to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)

This funding opportunity supports research activities that advance NIAID’s mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains.

Award Budget and Period: Up to $500K (direct costs) per year for up to five years

Application Due Dates: June 5th, October 5th and February 5th

4. Generating New Insights and Mechanistic understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed)

This funding opportunity is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Award Budget and Period: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Post Submission Materials

Application Due Dates: June 5th, October 5th and February 5th

Biomedical Advanced Research and Development Authority


1. Broad Agency Announcement

BARDA solicits proposals for research and development of medical countermeasures for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population.

R&D areas of interest include: CBRN antitoxins and therapeutic proteins; clinical diagnostics; emerging infectious diseases (including SARS-CoV-2); Influenza and emerging infectious diseases (IEID) therapeutics, including Influenza therapeutics and COVID-19 therapeutics; advanced manufacturing technologies

Application Due Dates: Quad Charts/White Papers and the Full Proposal submission deadline is October 31, 2020.

2. CARB-X (Combating Antibiotic-Resistant Bacteria)

This funding opportunity addresses antibiotic resistance. It supports the development of the most innovative products that protect human health from the most serious bacterial threats, including therapeutics of all types, preventives such as vaccines, diagnostics and devices. In the first year, the CARB-X portfolio will primarily focus on therapeutics to treat Gram-negative bacteria on the Serious or Urgent Threat List prepared by the CDC as well as any non-traditional approaches.

Department of Defense


1. Defense Advanced Research Projects Agency (DARPA) – Broad Agency Announcement – Biological Technologies

This opportunity aims to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences.

Award Budget and Period: Multiple awards are possible. The amount of resources made available under this BAA will depend on the quality of the proposals received and the availability of funds.

Application Due Dates: Rolling deadline

2. USAMRMC Broad Agency Announcement for Extramural Medical Research

The Military Infectious Diseases Research Program (MIDRP) focuses on vaccines, drugs, vector detection assays, and novel prevention strategies and therapeutics to treat microbial infections.

Funding opportunities include research and development toward preventive measures for infectious diseases (vaccines, anti-parasitic drugs, vector control products, combat wound infections) and research and development of therapeutic measures for infectious diseases (therapeutic drug development, drug delivery systems, novel medical countermeasures).

Award Budget and Period: Budget not limited, needs to be well-justified. Project duration up to 5 years.

Application process: Pre-application and a full application (pending invitation)

Application Due Dates: rolling deadline until September 30, 2022

3. Defense Threat Reduction Agency (DTRA) – Science and Technology New Initiatives

DTRA’s mission is to protect America and its allies from Weapons of Mass Destruction (WMD) (chemical, biological, radiological, nuclear, and high-yield explosives (CBRNE)). This broad agency announcement (BAA) provides a tool to search for and execute strategic investments in innovative technologies for countering WMD. This BAA is focused on innovative R&D that advance technical state-of-the-art or increase knowledge and understanding of overarching challenges for countering WMD.

Areas of interest include: Chemical/Biological defense solutions (therapeutics, diagnostics, detection etc.), and counter WMD (including combating biological or chemical terrorism)

Award Budget and Period: No specified limitations. Budget must be well justified.

Application Due Dates: Open on Rolling basis